CRISPR Therapeutics AG financial data

Symbol
CRSP on Nasdaq
Location
Zug
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1528% % -19%
Debt-to-equity 18% % 6.6%
Return On Equity -32% % -71%
Return On Assets -27% % -69%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 95,985,312 shares 12%
Common Stock, Shares, Outstanding 95,894,341 shares 12%
Entity Public Float $4,100,000,000 USD -4.7%
Common Stock, Value, Issued $3,087,000 USD 14%
Weighted Average Number of Shares Outstanding, Basic 89,925,109 shares 6.6%
Weighted Average Number of Shares Outstanding, Diluted 89,925,109 shares 6.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $3,510,000 USD -91%
Research and Development Expense $284,806,000 USD -8.2%
General and Administrative Expense $73,542,000 USD 0.77%
Operating Income (Loss) $664,571,000 USD -42%
Nonoperating Income (Expense) $86,606,000 USD -17%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $577,965,000 USD -59%
Income Tax Expense (Benefit) $3,634,000 USD 1.3%
Net Income (Loss) Attributable to Parent $581,599,000 USD -59%
Earnings Per Share, Basic -6.47 USD/shares -49%
Earnings Per Share, Diluted -6.47 USD/shares -49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $347,559,000 USD 17%
Marketable Securities, Current $1,628,269,000 USD 1.4%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD -100%
Assets, Current $1,985,671,000 USD 2.5%
Property, Plant and Equipment, Net $115,851,000 USD -14%
Operating Lease, Right-of-Use Asset $131,724,000 USD -8.2%
Other Assets, Noncurrent $24,368,000 USD 54%
Assets $2,265,243,000 USD 1%
Accounts Payable, Current $11,138,000 USD -24%
Employee-related Liabilities, Current $12,966,000 USD -30%
Accrued Liabilities, Current $89,407,000 USD 118%
Contract with Customer, Liability, Current $15,771,000 USD 310%
Liabilities, Current $149,120,000 USD 70%
Contract with Customer, Liability, Noncurrent $0 USD -100%
Operating Lease, Liability, Noncurrent $188,168,000 USD -8.8%
Other Liabilities, Noncurrent $6,142,000 USD 78%
Liabilities $343,430,000 USD 11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,821,000 USD 162%
Retained Earnings (Accumulated Deficit) $1,947,551,000 USD -43%
Stockholders' Equity Attributable to Parent $1,921,813,000 USD -0.53%
Liabilities and Equity $2,265,243,000 USD 1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $53,947,000 USD -149%
Net Cash Provided by (Used in) Financing Activities $10,588,000 USD -97%
Net Cash Provided by (Used in) Investing Activities $19,755,000 USD 80%
Common Stock, Shares Authorized 132,477,166 shares 0%
Common Stock, Shares, Issued 96,009,657 shares 12%
Common Stock, Par or Stated Value Per Share 0.03 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $63,073,000 USD -120%
Deferred Tax Assets, Valuation Allowance $345,395,000 USD 22%
Deferred Tax Assets, Gross $410,488,000 USD 15%
Operating Lease, Liability $206,746,000 USD -7.6%
Depreciation $19,400,000 USD 1%
Payments to Acquire Property, Plant, and Equipment $206,000 USD -71%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $578,618,000 USD -58%
Lessee, Operating Lease, Liability, to be Paid $265,572,000 USD -9.9%
Property, Plant and Equipment, Gross $206,903,000 USD 0.26%
Operating Lease, Liability, Current $18,578,000 USD 7.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two $28,798,000 USD -2.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $29,684,000 USD 0.91%
Operating Lease, Weighted Average Discount Rate, Percent 0.059 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $58,826,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three $28,206,000 USD -1.7%
Deferred Tax Assets, Operating Loss Carryforwards $241,462,000 USD 36%
Unrecognized Tax Benefits $50,709,000 USD 1.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $27,314,000 USD -3%
Depreciation, Depletion and Amortization $4,736,000 USD -2%
Deferred Tax Assets, Net of Valuation Allowance $65,093,000 USD -11%
Share-based Payment Arrangement, Expense $72,499,000 USD -16%